The Latest in Indolent Lymphoma

Venetoclax plus ibrutinib yields encouraging MRD results in first-line CLL

June 8, 2018

Ibrutinib plus rituximab amped PFS in Waldenström’s

June 1, 2018

Indolent Lymphoma

Older CLL and NHL patients are more vulnerable to toxicities

May 23, 2018

Physical inactivity linked to lymphoma risk

May 18, 2018

5-year data show deepening response with ibrutinib in CLL

May 11, 2018

In young MCL patients, optimal treatment may vary

May 4, 2018

Early results favor combo IL-15/anti-CD20 in indolent NHL

May 3, 2018

Indolent Lymphoma

Venetoclax shows muscle against CLL relapsed after idelalisib

April 18, 2018

FDA grants priority review of follicular lymphoma drug

April 11, 2018

Indolent Lymphoma

Updated CLL guidelines incorporate a decade of advances

April 6, 2018

FDA updates breast implant–associated lymphoma cases, risk

March 22, 2018

Ibrutinib linked to invasive fungal infections

March 7, 2018

Mycosis fungoides increases risk for second cancers

February 28, 2018

High objective response rate, OS seen with ATA129 in PTLD

February 24, 2018

Triple therapy ups response in refractory mantle cell lymphoma

February 4, 2018